<DOC>
	<DOCNO>NCT00879593</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disease affect motoneuron , prevalence around 5/100.000 . Respiratory muscle involvement major feature ALS remain main prognostic factor . Timing rate progression respiratory muscle involvement also highly variable among individual . Respiratory manifestation justify careful follow include clinical evaluation , pulmonary function test blood gas . Prognostic value respiratory muscle assessment clearly demonstrate ALS , although several cut value publish . The clinical benefit non invasive ventilation ( NIV ) well establish ALS , optimal criterion initiation remain debated . The 1999 consensus NIV select classical criterion consider NIV patient respiratory symptom suggest hypoventilation : daytime hypercapnia ( PaCO2 &gt; 45 mmHg ) , nocturnal SaO2 &lt; 89 % 5 consecutive minute progressive neuromuscular disorder ( NMD ) ( mainly ALS ) , vital capacity ( VC ) &lt; 50 % pred PImax &lt; 60 cmH2O . Besides daytime clinical PFT assessment , nocturnal evaluation essential ALS . The prevalence sleep apnea range 16 % 76 % . Transcutaneous PCO2 ( tcPCO2 ) attractive technique evaluate non invasively nocturnal hypoventilation . The technique well validated different setting . Its use neuromuscular disorder ( NMD ) recent . In particular one study demonstrate high predictive value tcPCO2 development daytime hypoventilation within 1 year . To knowledge , technique specifically assessed ALS . There potential role nocturnal PtcCO2 monitoring close follow ALS patient . Indeed , close respiratory follow ALS patient essential determine optimal timing NIV , avoid occurence unexpected acute respiratory failure .</brief_summary>
	<brief_title>Nocturnal PtcCO2 Monitoring Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Amyotrophic lateral sclerosis : definite , probable probable EMG ( Airlie House Criteria , 1998 ) . Forced vital capacity &gt; 70 % pred . Daytime PaCO2 &lt; 43 mmHg . Venous HCO3 &lt; 28 mmol/L Patients unable perform pulmonary function test nocturnal recording . Coexisting significant lung disease : moderate severe asthma COPD Current NIV , CPAP oxygen therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>